Rankings
▼
Calendar
TNGX Q1 2025 Earnings — Tango Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena
TNGX
Tango Therapeutics, Inc.
$2B
Q1 2025 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$5M
-16.7% YoY
Gross Profit
$5M
100.0% margin
Operating Income
-$43M
-788.8% margin
Net Income
-$40M
-739.5% margin
EPS (Diluted)
$-0.36
QoQ Revenue Growth
+31.0%
Cash Flow
Operating Cash Flow
-$42M
Free Cash Flow
-$42M
Stock-Based Comp.
$7M
Balance Sheet
Total Assets
$274M
Total Liabilities
$108M
Stockholders' Equity
$167M
Cash & Equivalents
$58M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$5M
$6M
-16.7%
Gross Profit
$5M
$6M
-16.7%
Operating Income
-$43M
-$42M
-0.7%
Net Income
-$40M
-$38M
-5.2%
Revenue Segments
Collaboration Revenue
$5M
100%
← FY 2025
All Quarters
Q2 2025 →